Brookhaven National Lab News

Because you are not running JavaScript or allowing active scripting, some features on this page my not work. >> Enable Javascript <<

Site Navigation

General Information

Menu

BNL Home

Personality-Influencing Gene May be a Key to Long Life

Thursday, January 3, 2013

Drug-Related Choice Predicts Future Drug Use

Monday, December 17, 2012

EEG Provides Insight into Drug-Related Choice in Addiction

Tuesday, November 13, 2012

Drinking Alcohol Shrinks Critical Brain Regions in Genetically Vulnerable Mice

Wednesday, February 15, 2012

Gray Matter in Brain’s Control Center Linked to Ability to Process Reward

Tuesday, November 29, 2011

Cocaine Images Capture Motivated Attention Among Users

Monday, April 4, 2011

Miniature 'Wearable' PET Scanner Ready for Use

Sunday, March 13, 2011

Genetic Makeup and Duration of Abuse Reduce the Brain's Neurons in Drug Addiction

Monday, March 7, 2011

First Direct Evidence that Response to Alcohol Depends on Genes

Tuesday, October 19, 2010

Ritalin Improves Brain Function, Task Performance in Cocaine Abusers

Monday, September 6, 2010

New Findings Imply Exercise in Adolescence May Help Prevent Drug Abuse

Wednesday, August 4, 2010

European Patent Office Grants Patent for the Use of Vigabatrin/CPP-109 for the Prevention of Addiction to Opioids in Pain Management

Friday, July 9, 2010

Media Advisory: Visualizing "Your Brain on Drugs"

Friday, April 23, 2010

Brain Scan Study Shows Cocaine Abusers Can Control Cravings

Monday, November 30, 2009

Catalyst Pharmaceutical Partners Continues Clinical Development of CPP-109 for the Treatment of Cocaine and Methamphetamine Addiction

Wednesday, September 30, 2009

Deficits in Brain’s Reward System Observed in ADHD Patients

Tuesday, September 8, 2009

Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II Trial for Cocaine Addiction

Friday, May 29, 2009

Brain-Behavior Disconnect in Cocaine Addiction

Monday, May 25, 2009

Recent Drug Use Masks Cocaine Abusers' Cognitive Impairment

Tuesday, March 3, 2009

Control Your Hunger? Study Shows Men Can, Women Can't

Monday, January 19, 2009

Drug-Related Preference In Cocaine Addiction Extends to Images

Sunday, November 16, 2008

‘Insight’ Deficit May Explain Denial in Drug Addiction

Sunday, November 16, 2008

Hope for Treating Relapse to Methamphetamine Abuse

Thursday, November 13, 2008

Addiction Treatment Proves Successful in Animal Weight Loss Study

Wednesday, August 20, 2008

Gene Therapy Reduces Cocaine Use in Rats

Wednesday, April 16, 2008

Cocaine's Effects on Brain Metabolism May Contribute to Abuse

Monday, February 18, 2008

Catalyst Pharmaceutical Partners Begins Enrollment for its U.S. Phase II Clinical Trial of CPP-109 in Patients With Cocaine Addiction

Friday, January 25, 2008

Catalyst Pharmaceutical Partners Announces Positive Phase II Trial Results for Vigabatrin in the Treatment of Cocaine Addiction

Friday, December 7, 2007

Cocaine Abuse Blunts Sensitivity to Monetary Reward

Wednesday, November 7, 2007

Catalyst Pharmaceutical Partners, Inc. Initiates U.S. Phase II Clinical Trial of CPP-109 in Patients With Cocaine Dependence

Tuesday, July 10, 2007

Brookhaven Lab Chemist to Discuss 'Imaging Drug Addiction' at Harborfields Public Library, June 28

Friday, May 25, 2007

Addiction and the Brain: Are We Hard-Wired to Abuse Drugs?

Monday, February 12, 2007

Altered Perception of Reward in Human Cocaine Addiction

Sunday, October 15, 2006

Developing Radiotracers for Imaging Studies in Addiction

Thursday, September 14, 2006

Catalyst Pharmaceutical Partners Says FDA Has Accepted IND Application for CPP-109 to Treat Cocaine Addiction

Monday, January 3, 2005

New MicroMRI Facility Expands Lab's Brain-Imaging Capabilities

Monday, November 15, 2004

Proposed Addiction Treatment Successful, Safe in Second Small Trial

Monday, November 15, 2004

Results From First Clinical Trial Using GVG to Treat Addiction

Monday, September 22, 2003

Proposed Addiction Treatment Blocks Environment-Triggered Craving

Wednesday, March 7, 2001

Brookhaven Lab Awards License to David Pharmaceuticals, Inc. for Potential Addiction Treatment

Thursday, September 9, 1999

Epilepsy Drug Stops Nicotine's Effects in Animals

Wednesday, December 2, 1998

Epilepsy Drug Found to Stop Cocaine's Effects in Animals

Wednesday, August 5, 1998

Featured Video

362

Brookhaven Lab: Science Happens Here
Wednesday, March 13, 2013

From a World War I U.S. Army base to a world-renowned center of high-tech research: See how our site and our science have evolved to meet the challenges of the 21st Century.

Image Gallery

More images on Flickr

Brookhaven Bits & Bytes on ScienceBlogs.com

Tweets by @BrookhavenLab

One of ten national laboratories overseen and primarily funded by the Office of Science of the U.S. Department of Energy (DOE), Brookhaven National Laboratory conducts research in the physical, biomedical, and environmental sciences, as well as in energy technologies and national security. Brookhaven Lab also builds and operates major scientific facilities available to university, industry and government researchers. Brookhaven is operated and managed for DOE's Office of Science by Brookhaven Science Associates, a limited-liability company founded by the Research Foundation for the State University of New York on behalf of Stony Brook University, the largest academic user of Laboratory facilities, and Battelle, a nonprofit applied science and technology organization.

Site Index | Privacy and Security Notice | Report a Problem With This Page

BSA logos